Back to Research

Organization profile

Ilonov

Ilonov is a preclinical-stage biopharmaceutical company focused on developing first-in-class biotherapies for diabetes and metabolic disorders by leveraging the muscle secretome. Its lead asset, ILV-001, is a naturally occurring myokine designed to restore metabolic balance, protect insulin-secreting islets, and potentially provide a functional cure for Type 1 Diabetes.

Allschwil, SwitzerlandFounded 2021

Overview

1. Executive Summary (Confidence: High)

Ilonov, founded in 2020 as a spin-off of the European Diabetes Study Center (CeeD) in Strasbourg, is a French-Swiss biotech entity uniquely positioned at the forefront of the longevity ecosystem. The organization treats skeletal muscle as an endocrine organ, harvesting the therapeutic potential of myokines—hormones naturally secreted during exercise—to regulate systemic metabolism. Their primary mission is to alleviate the burden of daily diabetes management and eliminate severe age-related complications like renal failure. As of March 2025, Ilonov has joined the BaseLaunch portfolio and entered a research collaboration with a leading pharmaceutical partner to explore the biological mechanisms of their lead candidate, ILV-001. This strategic shift aims to validate the "muscle-pancreas crosstalk" as a major new therapeutic domain for chronic diseases and longevity.

Unlock the full profileGet the complete company dossier

This public view only shows an extract. Open the full profile to access the complete company intelligence record, including the full write-up and structured research details.

Desktop only

Research is currently available on desktop only.

The Research module is designed for larger screens. Please reopen it on a desktop or laptop to use the screener, filters, detail pages, and admin tools.